Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer
- 7 May 2020
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 98 (7), 501-511
- https://doi.org/10.1159/000506075
Abstract
Introduction: Anti-programmed cell death 1 (PD-1) therapies have shown promising clinical activity against gastric cancer (GC). We evaluated the clinical significance of immune-related gene expression in GC tissues to better understand the tumor immune microenvironment. Methods: PD-1, PD-1 ligand 1 (PD-L1) and CD8 mRNA levels and clinicopathological factors, including survival, were examined by quantitative RT-PCR in 155 GC patients who underwent surgery. PD-1 and PD-L1 expression in tumor tissue from 24 GC patients was investigated by immunohistochemical analysis. Results: PD-1, PD-L1 and CD8 mRNA levels were significantly lower in tumor tissue than in normal tissue (p < 0.0001, p < 0.05, and p < 0.0001). GC patients with low PD-1, PD-L1 and CD8 mRNA levels had significantly poorer overall survival (OS) than those with high PD-1, PD-L1 and CD8 mRNA levels, respectively (p < 0.001, p < 0.01 and p < 0.05). Low PD-1, PD-L1 and CD8 mRNA levels were more significantly associated with poor prognosis in undifferentiated-type GC patients than in differentiated-type GC patients (PD-1: differentiated p = 0.0071 vs. undifferentiated p = 0.0024; PD-L1: p = 0.6527 vs. p < 0.0001; CD8: p = 0.4465 vs. p < 0.05). Multivariate analysis showed that lymph node metastasis, peritoneal dissemination, distant metastasis, low PD-1 mRNA levels and low CD8 mRNA levels were independent prognostic factors for worse OS (low PD-1 mRNA level: OR 2.16, 95% CI 1.10–4.58, p < 0.05; low CD8 mRNA level: OR 2.55, 95% CI 1.12–6.90, p < 0.05). PD-1 and PD-L1 mRNA levels in immune cells were significantly associated with PD-1 and PD-L1 protein levels (both p < 0.05), respectively. Conclusions: PD-1, PD-L1 and CD8 mRNA levels may reflect antitumor immunity in GC, and low PD-1 and CD8 mRNA levels are potential predictive biomarkers for poor prognosis in GC patients who underwent surgery.This publication has 29 references indexed in Scilit:
- PD-L1 is an independent prognostic predictor in gastric cancer of Western patientsOncotarget, 2016
- Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stromaGut, 2016
- Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resectionGastric Cancer, 2015
- A Long Non-coding RNA Activated by Transforming Growth Factor-β is an Independent Prognostic Marker of Gastric CancerAnnals of Surgical Oncology, 2015
- Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancerGastric Cancer, 2014
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- Comprehensive molecular characterization of gastric adenocarcinomaNature, 2014
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human CancerImmunity, 2013
- Clinical impact of programmed cell death ligand 1 expression in colorectal cancerEuropean Journal of Cancer, 2013
- PrognoScan: a new database for meta-analysis of the prognostic value of genesBMC Medical Genomics, 2009